Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBT Margin (2017 - 2025)

Assembly Biosciences has reported EBT Margin over the past 8 years, most recently at 52.01% for Q4 2025.

  • Quarterly results put EBT Margin at 52.01% for Q4 2025, up 19353.0% from a year ago — trailing twelve months through Dec 2025 was 8.47% (up 13125.0% YoY), and the annual figure for FY2025 was 8.47%, up 13125.0%.
  • EBT Margin for Q4 2025 was 52.01% at Assembly Biosciences, up from 85.23% in the prior quarter.
  • Over the last five years, EBT Margin for ASMB hit a ceiling of 52.01% in Q4 2025 and a floor of 300.66% in Q3 2021.
  • Median EBT Margin over the past 4 years was 133.19% (2024), compared with a mean of 125.08%.
  • Biggest five-year swings in EBT Margin: tumbled -29098bps in 2021 and later soared 19353bps in 2025.
  • Assembly Biosciences' EBT Margin stood at 300.66% in 2021, then soared by 49bps to 152.58% in 2023, then increased by 7bps to 141.51% in 2024, then skyrocketed by 137bps to 52.01% in 2025.
  • The last three reported values for EBT Margin were 52.01% (Q4 2025), 85.23% (Q3 2025), and 105.94% (Q2 2025) per Business Quant data.